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Phospho-peptideHomo sapiens ECT2 is a cell cycle regulator that plays critical roles in cytokinesis. ECT2 activity is
restrained during interphase via intra-molecular interactions that involve its N-terminal triple-
BRCT-domain and its C-terminal DH–PH domain. At anaphase, this self-inhibitory mechanism is
relieved by Plk1-phosphorylated CYK-4, which directly engages the ECT2 BRCT domain. To provide
a structural perspective for this auto-inhibitory property, we solved the crystal structure of the
ECT2 triple-BRCT-domain. In addition, we systematically analyzed the interaction between the
ECT2 BRCT domains with phospho-peptides derived from its binding partner CYK-4, and have iden-
tiﬁed Ser164 as the major phospho-residue that links CYK-4 to the second ECT2 BRCT domain.
Structured summary of protein interactions:
ECT2 and CYK-4 bind by isothermal titration calorimetry (1, 2, 3, 4, 5, 6, 7)
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction NIH/3T3 cells by Miki and colleagues as a transforming proteinDuring the telophase of cell division, cytokinesis is a separate
and important process to ensure accurate chromosome segrega-
tion. In metazoan cytokinesis, a contractile ring made of non-
muscle myosin II and actin ﬁlaments, locates at the cell cortex
and constricts the plasma membrane to form the cleavage furrow.
The assembly of the contractile ring is controlled by RhoA GTPase
[1,2], which promotes actin polymerization and myosin activity at
the nascent furrow [3]. Normally, GTPases regulate cell processes
by switching between GTP-bound (active) and GDP-bound
(inactive) forms. This state conversion of Rho family GTPases is
regulated by GEFs, which is especially prominent amongst protein
members that contain DH–PH domains [4].
The epithelial cell transforming protein 2 (ECT2) plays a critical
role as a Rho exchange factor [3,5–7]. ECT2 was ﬁrst identiﬁed inwith the binding speciﬁcities for Rho family proteins [8]. Pebble,
the Drosophila orthologue of ECT2, was also found to be a key
regulatory component of the Rho signaling pathway during cytoki-
nesis [9]. Although Homo sapiens ECT2 has been shown to increase
the exchange activity of at least three GTPases in vitro, including
RhoA, Cdc42, and Rac1 [10,11], current evidence suggests that
RhoA may represent a major ECT2-target in vivo [3,5,7,12]. More
recently, ECT2 has also been implicated in TWEAK-Fn14-directed
glioma cell migration and invasion by activating Cdc42 and Rac1
[13].
At its N-terminus, ECT2 contains triple copies of the BRCT
domain [14], which are separated from the C-terminal DH–PH
domain by a linker composed of about 120 amino acids. The ordin-
ary BRCT domains are often identiﬁed in proteins as singleton or
tandem pair [14], such as the C-terminal domain of XRCC1 [15]
as a singleton and 53BP1 [16] as the tandem pair. Until recently,
the ﬁrst structure of closely linked triple-BRCT has been deter-
mined, which locates at the N-terminus of TopBP1 [17]. In most
tandem BRCT domains, the ﬁrst domain offers a binding pocket
for phosphorylated residues, whereas the BRCT–BRCT interface
assists the ﬁrst one to form a hydrophobic core and affords the
binding speciﬁcity for the +3 position residue of the phospho-
peptides [18].
Table 1
Data collection and reﬁnement statistics. Rmerge =
P
|Ii-hIi|/P|i|, where Ii is the
intensity of an individual reﬂection and hIi is the average intensity of that reﬂection.
Rfactor =
P
||Fobs|-|Fcalc||/
P
|Fobs| for all reﬂections, Rfree was calculated on the 5% of
data excluded from reﬁnement.
ECT2–BRCT domains*
Data collection
Space group H3
Cell dimensions
a, b, c (Å) 123.700, 123.700, 89.244
a, b, c () 90.00, 90.00, 120.00
Molecules per asymmetric unit 1
Wavelength (Å) 0.9790
Resolution (Å) 50.00–3.10 (3.16–3.10)
Rmerge 0.098 (0.883)
I/rI 12.6 (2.4)
Completeness (%) 99.9 (99.8)
Redundancy 4.4 (4.4)
Reﬁnement
Resolution (Å) 36.873–3.106 (3.186–3.106)
No. reﬂections 9156
Rfactor/Rfree (%) 21.4/28.0
No. atoms of protein 2142
Average B-factors 106.5
R. m. s deviations
Bond lengths (Å) 0.012
Bond angles () 1.655
Ramachandran plot (%)
Most favored regions 85.9
Additional allowed regions 98.2
Generously allowed regions 100
PDB entry 4N40
* As the Se-Met labelled crystal has higher resolution than the native one in this
case, it is used as the only data set for structural determination.
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called CYK-4 colocalize at the central spindle via mitotic kinesin-
like protein (MKLP1), and ECT2 then plays its due role until the
midbody stage [3,7,12,19,20]. Both the BRCT domains of ECT2
and the N-terminus of CYK-4 can be phosphorylated by the mam-
malian Polo-like kinase Plk1 [21,22], which plays a critical role to
coordinate cytokinesis [23]. Recently, Wolfe et al. proposed that
four sites within amino acids 139–174 of CYK-4 are phosphory-
lated by Plk1 and that these phosphorylations greatly enhanced
the interaction between CYK-4 and ECT2 [21]. Previous studies
have implicated that ECT2 activates RhoA through the interaction
with CYK-4 [10,19], on condition that the auto-inhibition between
triple-BRCT-domain and RhoGEF of ECT2 is relieved [24].
Remarkable progress towards ECT2-related regulation in cyto-
kinesis has been made over the past years. However, there remain
questions open to be answered. For example, how ECT2 BRCT
domains recognize the multiple phosphorylated sites on CYK-4?
Controversial in vivo data have been reported about the contribu-
tions of different phospho-serines to the interaction between ECT2
and CYK-4 [21,22]. Therefore it remains of signiﬁcant interest to
investigate the dynamic molecular regulatory mechanism that
underlies the ECT2 BRCT domains-dependent interaction with
CYK-4.
In this study, we determined the crystal structure of the
N-terminal triple-BRCT-domain of ECT2 and analyzed its interac-
tion with phosphorylated peptides derived from CYK-4 N-terminus
using site-directed mutagenesis and isothermal titration calorime-
try (ITC). Further in vitro GTPase activity measurements conﬁrmed
that the speciﬁc recognition we identiﬁed between ECT2 and CYK-
4 is capable of disrupting the auto-inhibition of ECT2.
2. Materials and methods
2.1. Protein cloning, expression and puriﬁcation
The triple-BRCT-domain of ECT2 (UniProt Q9H8V3) was
expressed and puriﬁed using standard procedures for Seleno-
methionine (Se-Met) labelled proteins, the DP–PH domain of ECT2
and the full length of RhoA were expressed and puriﬁed by general
methods. The details are presented in Supplementary material.
2.2. Crystallization and data collection
The Se-Met labelled ECT2 (22-326) was concentrated to 10 mg/
ml and added with glycerol to 1% (v/v). The protein was then crys-
tallized with the hanging-drop vapor-diffusion method at 20 C, by
mixing 1 ll protein and 1 ll of 0.1 M MES, pH 6.0, 14% (w/v) Meth-
oxy Polyethylene Glycerol (MPEG) 5000. Tiny crystals were visible
within 12 h, which were then pounded to pieces and seeded to
obtain larger crystals. Similarly, the seeded crystals became visible
in 12 h, and took 2 days to reach the maximum size. The cryopro-
tectant for crystals was 70% reservoir solution supplemented with
30% glycerol. The crystals were preserved in liquid nitrogen stream
at 100 K. The diffraction data was collected at 100 K on beamline
BL17U with an MX-225 CCD (Marresearch, Germany) at the Shang-
hai Synchrotron Radiation Facility (SSRF).
2.3. Model building and reﬁnement
Data were processed and scaled using HKL2000 [25] and CCP4
program package [26]. Phases were determined by a single-
wavelength anomalous dispersion experiment. The initial model
was built automatically by Buccaneer in CCP4 package [26]. The
model was then further modiﬁed and reﬁned through a combina-
tion of the PHENIX suite [27], Refmac5 [28] in CCP4 package andCoot [29]. The quality of the structure was validated with PRO-
CHECK [30]. The details during data collection and reﬁnement
are presented in Table 1.
2.4. Small-angle X-ray scattering
The small-angle X-ray scattering (SAXS) data were recorded on
the beamline 12ID-B of the Advanced Photon Sources (APS) at
Argonne National Laboratory with a wavelength of 1.033 Å. Addi-
tional details are provided in Supplementary material.
2.5. MD simulations
MODELLER [31] was used to add a few residues which were
missing in the N-terminal region of crystal structure of ECT2
(22-326). Starting with this initial model, a MD simulation of
triple-BRCT-domain was performed with a parallel implementa-
tion of the GROMACS-4.5.5 package [32], using the CHARMM27
force ﬁeld [33]. Additional details are presented in Supplementary
material.
2.6. Isothermal titration calorimetry (ITC)
The peptides used in this assay were selected from CYK-4
(UniProt Q9H0H5) and purchased from GL Biochem (Shanghai)
Ltd., including pS149 (LSTIDE[pS]GSILSDI), pS157 (SILSDI[pS]
FDKTDE), pS164 (SFDKTDE[pS]LDWDSSL), pS170 (ESLDWDS[pS]
LVKTFKL), pS164-W167A (SFDKTDE[pS]LDADSSL), pS157long (SIL
SDI[pS]FDKTDESLDWDSSLE), pS157/pS164 (SILSDI[pS]FDKTDE[pS]
LDWDSSLE), pS164long-S157A (SILSDIAFDKTDE[pS]LDWDSSLE),
and S164 (SFDKTDESLDWDSSL), where [pS] corresponds to
phospho-serine.
Y. Zou et al. / FEBS Letters 588 (2014) 2911–2920 2913The protein samples and peptides for ITC were buffered in
30 mM Tris, pH 8.0, 200 mM NaCl and 1 mM EDTA. ITC measure-
ments were carried out at 20 C using an ITC-200 Microcal calorim-
eter (Microcal, GE healthcare). All peptides were at a concentration
of 6 mM. A volume of 200 ll protein at 200 lM was titrated with
peptide in 20 injections of 2 ll each with 2 min intervals between
injections. Control titrations with isometric buffers instead of pro-
tein samples were subtracted to account for heat dilution. The data
were analyzed with the program Origin version 7 provided by Mic-
rocal, which were ﬁt to a one-site binding model.
2.7. Circular dichroism spectroscopy
The Circular dichroism (CD) spectra of ECT2 (22-326) and its
mutants were performed on a Jasco-810 spectropolarimeter. The
experiments were carried out at 25 C with wavelengths between
190 and 260 nm using a 0.1-cm path length cell. The protein sam-
ples were concentrated to 0.1 mg/ml in buffer with 30 mM phos-
phate (pH 8.0), a buffer-only sample was used as the reference.
All CD spectra were an average of three successive results. The
molar ellipticities ([h]) were plotted against wavelength, and the
reference curve was subtracted from each curve.
2.8. In vitro ﬂuorescent measurements of GEF activity
Fluorescence-based kinetic assays were performed in Spectra-
Max M5 (Molecular Devices) with a ﬂuorescence analog of GTP
called BODIPY TR GTP (Life Technologies Corporations) [34,35],
which is measured by excitation at 580 nm and emission at
620 nm. All the samples were ﬁrst dialyzed to a low-salt buffer
(20 mM Tris, pH 8.0 and 50 mM NaCl). The measurements wereFig. 1. Overall structure of triple-BRCT-domain of ECT2. (A) Domain architectonics of ECT
are formed by residues 45–137, 138–236, and 237–326, respectively. The DH–PH domain
(B) The crystal structure of ECT2 (22-326). BRCT0, BRCT1, and BRCT2 domains are coloredrecorded at 25 C in the low-salt buffer in the presence of 1 lM
RhoA-GDP and 1 lM BODIPY TR GTP. The reaction systems were
strictly controlled at a volume of 200 ll. Different concentrations
of triple-BRCT-domain of ECT2 as an inhibitor was incubated for
20 min with 0.5 lM DH–PH domain of ECT2 before initiating the
reaction with BODIPY TR GTP. The relative ﬂuorescence was mon-
itored for 10 min and measurements were taken every 20 s. Protein
free buffer with 1 lM BODIPY TR GTP was set as reference. The
data was processed with the program Origin version 8. All the data
curves were an average of three independent results and the refer-
ence curve was subtracted from each curve.
3. Results
3.1. Overall Structure of triple-BRCT-domain of ECT2
The N-terminal region (residue 22-326) of ECT2 was expressed
with a selenomethionine supplemented medium, and its crystal
structure was determined at a resolution of 3.1 Å (Table 1), missing
23 residues at the N-terminus (residues 22–44). Our structure con-
ﬁrmed that the ECT2 N-terminus contains three predicted BRCT
domains formed by residues 45–137, 138–236, and 237–326,
respectively, which are packed in a head-to-tail manner (Fig. 1).
To be consistent with the published nomenclature [17], these three
BRCT domains are referred to as BRCT0, BRCT1, and BRCT2.
Except BRCT2 which lacks the a2 helix between b3 and b4
strands, the other two BRCT domains of ECT2 all exhibit a conven-
tional b1-a1-b2-b3-a2-b4-a3 topology: the central four-stranded
b-sheets (b1, b2, b3 and b4) surrounded by two helices (a1 and
a3) on the one side and one helix (a2) on the other side. Unlike
a canonical BRCT domain which adopts a parallel b-sheets motif,2. There are 883 residues altogether in full length of ECT2. BRCT0, BRCT1, and BRCT2
is formed by residues 411–807 according to our experiments in protein expression.
blue, green, and red, respectively. The linkers between domains are showed in gray.
2914 Y. Zou et al. / FEBS Letters 588 (2014) 2911–2920the central b-sheets in BRCT domains of ECT2 are perpendicular to
each other, which has only been observed before in triple-BRCT-
domain of TopBP1 (1-290, Fig. 2B). Normally the linker between
tandem-BRCT-domain contains more than 30 amino acids, such
as BRCA1, 53BP1, Crb2, PTIP and MCPH1 [16,36–39]. However,
there are only 19 amino acids between BRCT0 and BRCT1, and 23
amino acids between BRCT1 and BRCT2 in ECT2 (Fig. 1B), basically
consistent with the shorter linkers (17 and 22 amino acids) in
TopBP1 (1-290), suggesting triple-BRCT-domain of ECT2 and
TopBP1 may represent a new type of consecutive BRCT domains.
In the crystal structure, three BRCT domains of ECT2 are
arranged as a line similarly as their counterparts in TopBP1
(Fig. 1B). To learn whether this linear arrangement is maintained
in solution state, SAXS experiment was further employed to inves-
tigate overall shape of ECT2 (22-326). Unexpectedly, the analysis of
SAXS data showed that one third of the SAXS envelop tilts 40
towards the other part (Fig. S1C). To explain this phenomenon,
we examined the atomic coordinates of ECT2 and found that the
temperature factors of the Ca atoms of BRCT2 domain are singu-
larly higher than those of BRCT0 and BRCT1 domains (Fig. S2), sug-
gesting that BRCT2 of ECT2 is more ﬂexible than the other two
domains, consistent with the surface area buried between domains
(Table S1, Fig. S3). Furthermore, using molecular dynamics (MD)
simulation, we calculated the most probable conformation of
ECT2 (22-326) in solution, which matches to the SAXS envelop
with a chi value of 0.372 (Fig. S1C). In the simulated structure,
ECT2 (22-326) adopts a bended conformation with the BRCT2
domain obviously slant to the other two BRCT domains, inconsis-
tent with crystal structure we obtained. We propose that the linear
arrangement of three BRCT domains in the crystal structure might
be partly due to the crystal packing.
3.2. Structural comparison of the BRCT domains of ECT2 with other
BRCT domains
ECT2 (22-326) was analyzed in NCBI Blast, and the sequence
identities with known BRCT domains are all below 33%. Three BRCT
domains of ECT2 were compared separately with some known
BRCT domains which have higher sequence identities (Fig. S4).
Out of them BRCT0 is the one with the lowest sequence identity
in ECT2. The sequence comparison of ECT2 among different species
also revealed that BRCT0 is the most variable one out of the three
BRCT domains during the evolution (Fig. 2A), which might explain
why there were different views on whether ECT2 N-terminus con-
tains a tandem-[40] or triple-[14] BRCT-domain.
As the only two proteins which contain triple-BRCT-domain so
far, ECT2 and TopBP1 share a similar cylinder-like crystal structure
and distribution of secondary structure. However, our structural
comparison indicated that there are several major differences
between them. In the BRCT0 domain, both ECT2 and TopBP1 have
a short 310 helix, which locates in ECT2 at the front of a1 helix but
in TopBP1 behind a1 helix (Fig. 2A). In addition, some of the helices
exhibit different orientations in two structures, especially those in
BRCT0 domain (Fig. 2B). Another major difference is that, in Top-
BP1, T208 of b1 strand and K250 of a2 helix constitute a generic
recognition motif for phospho-peptide on the surface of BRCT2
domain [17] (Fig. 2E). In ECT2, however, BRCT2 domain lacks the
a2 helix (Fig. 2C), which in turn affects the ability of BRCT2 domain
in binding phospho-peptides.
3.3. PS164 binds to the canonical phospho-serine binding pocket on
BRCT1 domain
Plk1-phosphorylated CYK-4 has been shown to bind the
N-terminus of ECT2 to further target ECT2 to the spindle midzone
[22]. In addition, Wolfe et al. claimed that the possible sitesphosphorylated by Plk1 are within amino acids 139–174 of CYK-
4, which is a part of the linker region between C–C domain and
C1 domain of CYK-4, and four putative sites for Plk1 phosphoryla-
tion are within this region, which are S149, S157, S164, and S170,
respectively (Fig. 3A). These four phosphorylation sites are all
highly conserved across different species (Fig. 3B) [21]. Impor-
tantly, Burkard et al. also conﬁrmed S157, S164, and S170 as phos-
phorylation sites using tandem mass spectrometry analysis of a
puriﬁed CYK-4 fragment following Plk1 phosphorylation in vitro
[22].
Our structural analysis indicated that there is only one canonical
binding site for phospho-serine in the crystal structure of ECT2
(22-326) (Figs. 2E and S5). Using immunoprecipitation blotting,
Burkard et al. proposed that phosphorylation of CYK-4 S157
generates a major docking site for ECT2 BRCT domains, although
other phospho-serines might also aid in stabilizing the ECT2–
CYK-4 interaction [22]. By contrast, using ITC our data indicated
that phospho-peptide encompassing CYK-4 pS164, but not its
non-phosphorylated counterpart, exhibited moderate ability
(Kd = 42 ± 4.1 lM) for ECT2 (22-326), while other phopho-peptides
containing pS149, pS157, or pS170 showed no detectable binding
with ECT2 (Figs. 3C and S6). These data led us to speculate that, of
the four phospho-residues, CYK-4 pS164 plays amajor role inmedi-
ating its interaction with ECT2 (22-326).
To further validate our ITC results, we mutated the putative key
residues in binding pocket of ECT2 based on the sequence
alignment and structural analysis with known BRCT domains
[14,17,36,41]. Three mutants (T153A, K195M, and T153A/K195M
double mutants) were therefore generated to test the binding
abilities with phospho-peptide pS164. ITC results show that the
binding afﬁnity of T153A reduced signiﬁcantly (Kd > 1000 lM)
while the binding abilities of K195M and T153A/K195M were
totally abolished (Fig. 4A and B). All the mutations did not alter
protein secondary structure according to the CD spectra (Fig. 4C).
Altogether our results state clearly that ECT2 (22-326) interacts
with pS164 of CYK-4 using the canonically conserved binding
pocket for phospho-serine in its second N-terminal BRCT domain
(BRCT1).
3.4. W167 at +3 position contributes signiﬁcantly to the interaction of
pS164 to ECT2
Previous studies showed that the hydrophobic residue located
at +3 position of phospho-serine plays an important role in the
recognition of tandem-BRCT-domain to phospho-peptides, via
the interaction with hydrophobic cores at the second domains
[38,42,43]. Interestingly, in phospho-peptide pS164, there is also
a hydrophobic residue (W167) located at +3 position, whereas
the orientation of BRCT2 in ECT2 is totally different from canoni-
cal tandem-BRCT-domain (Fig. S7B). To investigate whether this
residue also contributes to the interaction between pS164 and
ECT2 (22-326), we designed a mutant (W167A) of pS164 for ITC
analysis. Our results showed the alanine substitution at +3 posi-
tion reduced the binding of phospho-peptide pS164 with ECT2
(22-326) by more than 20-fold (Kd > 800 lM, Fig. 4D), indicating
that this hydrophobic residue does contribute importantly to the
recognition of ECT2 (22-326) to phospho-peptide. However, the
shorter linkers between BRCT1 and BRCT2 domains in ECT2 cause
an inter-domain rotation around the axis across three BRCT
domains, so that the hydrophobic core which is composed of a2
helix in BRCT1 and a1 and a3 helices in BRCT2 in tandem-
BRCT-domain is totally disrupted (Fig. S7), suggesting there might
be a different arrangement of hydrophobic pocket for speciﬁcity in
ECT2.
SinceW167 contributes a lot to the interaction between peptide
pS164 and ECT2 (22-326), we wonder if the interaction still exists
Fig. 2. Structural comparison between triple-BRCT-domain of ECT2 (orange) and TopBP1 (cyan). (A) Multiple sequence alignment of the following proteins: ECT2hs from H.
sapiens (Q9H8V3), ECT2mm fromM. musculus (Q07139), ECT2bt from B. taurus (A5D793), ECT2dr from D. rerio (Q4V9L0), ECT2xl from X. laevis (Q5XGV4), and TopBP1hs from
H. sapiens (Q92547). The secondary structure of BRCT domains of ECT2 and TopBP1 are shown above and below the sequence, respectively. Strictly and highly conserved
residues are showed separately in red background and in red characters. Residues that are involved in phospho-peptide binding are boxed in blue. (B) The crystal structure
comparison based on Ca atoms between triple-BRCT-domain of ECT2 (PDB: 4N40) and TopBP1 (PDB: 2XNH). (C) Highlighted comparison of BRCT2 domains. The area circled
by red dashed line shows that the a2 helix in BRCT2 of TopBP1 is not present in BRCT2 of ECT2. (D) Comparison of the phospho-serine binding pockets in BRCT1 of ECT2 and
TopBP1. The key residues are presented with side chains. The key distances are measured using PYMOL and showed with red dashed lines. (E) Comparison of the phospho-
peptide binding sites and the topologically equivalent sites in three BRCT domains of ECT2 and TopBP1. The residues which do have the ability to interact with phospho-
peptides are presented in orange (ECT2) and cyan (TopBP1), the others are colored gray.
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Fig. 3. Identiﬁcation of the phospho-peptide bound to ECT2 (22-326). (A) Domain architectonics of CYK-4 and a schematic of putative phosphorylated serine sites. W167 is
deﬁned as the +3 position residue of phospho-peptide pS164. (B) The conservation of CYK-4 (139–174) across different species. (C) The ITC measurements of the interactions
between ECT2 (22-326) and different phospho-peptides, including peptide pS149, pS157, pS164, and pS170.
2916 Y. Zou et al. / FEBS Letters 588 (2014) 2911–2920whenW167 is accompanied with other phospho-serines. After two
long peptides were tested, we found that peptide pS157long exhib-
its no binding to ECT2 (22-326) and peptide pS157/pS164 have
similar binding ability as peptide pS164 ((Kd = 43.1 ± 13.6 lM)
(Fig. S6), which suggests that pS157 cannot interact with ECT2
even if W167 is accompanied.3.5. N-terminal BRCT domains and its interaction with CYK-4 affect the
GEF activity of ECT2
During the anaphase of cell division, ECT2 activates RhoA
GTPase using the GEF activity of its C-terminal DH-PH domain,
which is inhibited by the N-terminus BRCT domains before
Fig. 4. Examination of key residues in the interaction between ECT2 (22-326) and peptide pS164. (A and B) The ITC measurements of the interactions between peptide pS164
and mutant ECT2s (22-326), including T153A, K195M, T153A/K195M, and R163E, of which the lines are overlapped. The thermodynamic parameters of ITC titrations in detail
are listed in Supplementary data (Table S2). (C) The CD spectra of ECT2 (22-326) and its mutants are overlapped. (D) The ITC measurement of the interaction between ECT2
(22-326) and the mutant at +3 position of peptide pS164–W167A.
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we ﬁrst measured the GTP-binding efﬁciency of RhoA which
reﬂects the GDP-dissociation efﬁciency of RhoA-GDP activated by
RhoGEF of ECT2. Furthermore, along with the addition of different
concentrations of ECT2 (22-326), the GTP-binding efﬁciency of
RhoA decreased in an inverse proportion (Fig. 5A). The initial
reaction rate of GTP-RhoA production decreased from 14.69 to
5.04 a.u./s, while the concentration of ECT2 (22-326) increased
from 0 to 50 lM (Fig. 5B). These results indicating that the
triple-BRCT-domain can independently inhibit the GEF activity of
C-terminal DH-PH domain of ECT2 in vitro.
Our ITC measurements revealed that there are speciﬁc interac-
tions between phospho-peptide pS164 and ECT2 (22-326). To learn
whether these interactions may directly lead to the release of the
auto-inhibition in ECT2, pS164 with increased concentrations from
20 to 100 lM were added stepwise into the above system, which
caused a large recovery of BRCT-inhibited GEF activity to RhoA
(Fig. 5C). When the concentration of added phospho-peptide
pS164 reached to 100 lM, the initial reaction rate of GTP-RhoA
production recovered to 14.40 a.u./s, which is very close to the
initial status without ECT2 (22-326) or phospho-peptide pS164
(Fig. 5D). According to some related models presented in previous
studies [3,24], our observation clearly indicated that pS164 of
CYK-4 can compete directly with ECT2 C-terminal DH-PH domain
for the interaction with its triple-BRCT-domain, which in turn
releases the auto-inhibition that involves the binding betweenthe N-terminal and C-terminal regions of ECT2, and subsequently
retrieve the GTPase activity of RhoA (Fig. 5E).4. Discussion
4.1. The possible role of multi-site phosphorylation of CYK-4 in the
interaction with ECT2
Multi-site phosphorylation is a common phenomenon in protein
post-translation modiﬁcations. The mode of multi-site phosphory-
lation often determines the extent and duration of a cellular
response [44]. In cell cycle regulation, the phosphorylation sites
of a given multi-site phosphorylation domain are often close to
each other, working together to enhance the interaction with other
proteins. [45,46]. Many kinds of domains have the ability to bind to
phosphorylated proteins, but only some of them could form domain
repeats to cater multi-site modiﬁcations, such as the tandem-
SH2-domain which binds multi-site phosphorylated proteins with
higher speciﬁcities than individual ones [47]. In the case of BRCT
domains, both ECT2 and TopBP1 were found to interact with
multi-phosphorylated proteins [17,21], suggesting multiple BRCT
repeats may relate to the recognition of multi-site phosphorylation.
Although it has been shown that CYK-4 is phosphorylated by
Plk1 at four putative sites before interacting with ECT2 (Fig. 3A),
how triple-BRCT-domain of ECT2 recognizes these phosphorylated
Fig. 5. The binding of peptide pS164 to ECT2 N-terminus relieves the auto-inhibition in ECT2. (A–D) Fluorescent measurements of GEF activities of ECT2. GEF, BRCTs, and
pS164 stand for DH–PH domain of ECT2, triple-BRCT-domain of ECT2, and peptide pS164 of CYK-4, respectively. The ‘‘negative’’ and ‘‘positive’’ stand for the GTP-binding
efﬁciency of RhoA without GEF, and with 0.5 lM GEF, respectively. The other curves reﬂect the change of the ﬂuorescent intensity (A) and the histogram reﬂects the initial
velocity of ﬂuorescent intensity change (B) upon the addition of different concentrations of ECT2 (22-326) into the solution containing C-terminal GEF of ECT2 and RhoA.
Further addition of different concentrations of peptide pS164 into above system causes the stepwise recovery of the ﬂuorescent intensity (C) and the initial velocity of
ﬂuorescent intensity change (D). (E) A cascade in cell cytokinesis, in which the interaction between ECT2 and phosphorylated CYK-4 plays a key role.
2918 Y. Zou et al. / FEBS Letters 588 (2014) 2911–2920sites remains unclear. Using immunoprecipitation assays, Wolfe
et al. reported that the mutation of any of the four residues alone
was insufﬁcient to inhibit the interaction between ECT2 and
CYK-4 [21]. By contrast, a similar study conducted by Burkard
and colleagues indicated that mutation of CYK-4 S157 largely abol-
ished the ECT2–CYK-4 interaction whereas mutations of the other
conserved serine residues resulted in no signiﬁcant difference.
Intriguingly, using ITC we found that CYK-4 pS164 speciﬁcally
interacted with ECT2 via a canonical binding pocket for phospho-
serine located on its second BRCT domain. On the contrary ECT2
(22-326) manifested negligible binding to phospho-peptides
encompassing the three other phosphorylation sites (ie pS149,
pS157, and pS170). Although CYK-4 pS164 plays a major role in
mediating its interaction with ECT2, we cannot exclude thepossibility that other phospho-serines may also contribute to the
interaction through weak binding with BRCT0 and/or BRCT2
domains, which is not sensitive to ITC technique. Combined with
the results from previous researches, we proposed that ECT2
adopts a multi-site recognition mechanism to interact with multi-
ple phosphorylated sites on CYK-4 for an elevated binding speciﬁc-
ity when a major docking site contributes signiﬁcantly to the
binding afﬁnity.
4.2. Irregular binding motif among BRCT domains
Two types of structural motifs are often seen at the phospho-
serine binding pockets in BRCT domains. Several canonical tan-
dem-BRCT-domains, including BRCA1, MDC1 and MCPH1, contain
Y. Zou et al. / FEBS Letters 588 (2014) 2911–2920 2919an R-X-X-K (R-X-X-N in MCPH1) motif, in which an arginine resi-
due locates between b3 strand and a2 helix and interacts directly
with the –COO terminus of +3 position residue of phospho-serine
peptides [38,41,48]. On the other hand, BRCT domains in Crb2 and
TopBP1 do not have an R-X-X-K motif. Instead, they have an
arginine at a1 helix, which composes the binding pocket with
conserved T/S and K, and interacts with phospho-serine directly
[17,49].
In ECT2, we have identiﬁed T153 and K195 as the key residues
for binding with phospho-peptide pS164. Though BRCT1 of ECT2
also has an arginine (R163) at a1 helix, which is similar as in Crb2
and TopBP1, however, this arginine is too far (18.2 Å) from the
binding pocket to interact with phospho-serine (Fig. 2E). In addi-
tion, the reduced binding afﬁnity between pS164 of CYK-4 and
R163E mutation of ECT2 triple-BRCT-domain (Kd = 187 ± 51.9 lM,
Fig. 5A and B) suggested that R163E is not a critical residue in the
binding of ECT2 BRCT1 with phospho-serine. This observation
might explain why ECT2 (22-326) binds peptide pS164 with a rela-
tively weak interaction (Kd = 42 ± 4.1 lM), which is 20-fold lower
than the binding ability of TopBP1 BRCT1 domain with phosphory-
lated peptide (Kd = 2.1 lM) [17]. This interaction is also a little
weaker than those determined for other BRCT domainswith the dis-
sociation constants (Kd) in a range of about 0.1–10 lM [38,43,50].
As we have indicated based on the measurements of GEF activ-
ity, ECT2 is a pivot in cytokinesis due to its auto-inhibition feature
and the upstream regulation by CYK-4 (Fig. 5E). At anaphase, the
auto-inhibition of ECT2 is released by CYK-4 binding. However,
at late telophase, a protein called FIP3 binds CYK-4 and dissociates
ECT2 from CYK-4 at the same binding region [51]. Therefore, the
interaction between ECT2 and CYK-4 should switch on and off
repeatedly during the cell cycles. The irregular binding we deter-
mined for BRCT domains of ECT2 with phospho-peptide is likely
related to its function so that the regulation of cell cytokinesis
occurs more rapidly and timely.
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